Cardiac stimulating apparatus having a blood clot filter and atrial pacer

Abstract

An apparatus is provided for reducing the formation and migration of blood clots from an atrial appendage, such as the left atrial appendage, to the blood vessel system of a patient. The apparatus comprises an atrial pacer to treat non-rheumatic atrial fibrillation (NRAF) of an atrial appendage so that the formation blood clots within the atrial appendage is decreased or eliminated. In addition, the apparatus includes a blood clot filter supported by the atrial pacer proximate the atrial appendage and the atrium to reduce the migration of blood clots from the atrial appendage into the blood vessel system of a patient.

Description

RELATED APPLICATIONS [0001] This is a continuation application of U.S. application Ser. No. 10 / 163,021, filed Jun. 4, 2002, which in turn claims the benefit of priority of U.S. Provisional Application No. 60 / 295,683, filed on Jun. 4, 2001, the entire contents of which application(s) are incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates generally to a device that deters migration of emboli from an atrial appendage into the vascular system of a patient, and more particularly to a device that includes a filter to deter such migration and a pacer to deter the formation of emboli such as blood clots within the atrial appendage. BACKGROUND OF THE INVENTION [0003] Non-rheumatic atrial fibrillation (NRAF) is associated with thromboembolic complications such as strokes. For example, when a thrombus or embolus occludes a vessel supplying blood to the brain, a stroke may result causing temporary or lasting paralysis of a part of the body or, in severe...

AI Technical Summary

Benefits of technology

[0012] An apparatus is provided for deterring the formation and migration of blood clots from an atrial appendage, such as a left or right atrial appendage, into the blood vessel system, i.e. vascular system, of a patient. In particular, an apparatus of the present invention comprises an atrial pacer to treat non-rheumatic atrial fibrillation (NRAF) or other arrhythmias of an atrial appendage so that the formation of blood clots within such atrial appendage is decreased or eliminated. In addition, the apparatus provides a blood clot filter to deter the migration of blood clots from an atrial appendage into the blood vessel system of a patient.

Problems solved by technology

For example, when a thrombus or embolus occludes a vessel supplying blood to the brain, a stroke may result causing temporary or lasting paralysis of a part of the body or, in severe cases, death.

Blockage of other blood vessels can occur as well causing attendant health concerns, including heart attack or gangrene.

A major problem associated with atrial fibrillation is pooling of blood in the left atrial appendage.

Such clots may travel from the left atrial appendage into the left atrium and into the vascular system, thereby increasing the danger of stroke or cardiac blockage.

However, both of these treatment approaches pose potential complications such as internal bleeding, as well as other negative side effects caused by the rate regulating therapeutic agents.

Such approaches are highly invasive and pose a risk of mortality to the patient.

However, Lesh et al. do not disclose a device or method suited to treat atrial fibrillation, or other arrhythmias of the heart, to thereby prevent the formation of clots in the left atrial appendage.

Such a situation may present a health concern as the left atrial appendage contracts and the blood enclosed therein is unable to exit the left atrial appendage.

Such contraction may result in an increased pressure in the left atrial appendage capable of weakening the wall of the left atrial appendage.

Additionally, as the barrier embodiment of Lesh et al. does not prevent the formation of clots, it is possible that the volume of the left atrial appendage may eventually be filled with coagulated blood.

Thus, filtering alone poses possible added health concerns.

Mower discloses a pacemaker that is capable of pacing the atria from multiple sites, but does not address prevention of migration of embolic material within the vascular system.

Moreover, neither Mower nor Lesh suggests combining a pacer with an embolic barrier for use in the heart.

Images